All stock reports

ARTEMISMED evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-08-27T23:39:22.756761+00:00

Metrics

latest_annual_period
2025-12-31
revenue
10812424000.0
net_income
1036192000.0
operating_cash_flow
1371352000.0
free_cash_flow
321884000.0
total_assets
14286539000.0
total_liabilities
4879750000.0
total_equity
9347128000.0
cash
2061415000.0
total_debt
2615600000.0
revenue_growth
0.15404325699392496
earnings_growth
0.25407802405544033
net_margin
0.09583345973113892
roe
0.11085672518874247
debt_to_equity
0.2798292694825619
cash_conversion
1.3234535684506346
free_cash_flow_margin
0.029769827746303698
trailing_pe
137.2708
forward_pe
0.0
peg_ratio
Not supplied
price_to_book
Not supplied
dividend_yield
0.0

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Trend Continuation Pullback

Research only. Direction: LONG.

Tests continuation after a controlled retracement within an established trend

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Price breach below slow EMA
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-b9d88b4fffb801a1d535d9c5b4d5336d852f7aec15cd316bc902930445e030f8
Policy
stock-decisions-v1
Evidence bundle hash
1a8c4bd31219da174bc3332115a436b0c4436dd44cbeb4d2491e9c53065ca2cb
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: b10a7aabf959d3130fa57c97be8687d37d2429a9e357d745d3e7d856936b121e
  • daily-price: 8264c1d3ce8b6d4c8b143c0b47840de0f634d07b8f856fe9f744ff0d2e3a637c
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

The cached financial metric revenue growth is 0.15404325699392496. The cached financial metric net margin is 0.09583345973113892. The cached financial metric roe is 0.11085672518874247. The cached financial metric debt to equity is 0.2798292694825619. The cached financial metric cash conversion is 1.3234535684506346. The cached financial metric free cash flow margin is 0.029769827746303698.

Risks

Price source verification: REPAIRED. The closing price was -8.24% below its highest close in the available trailing year. Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.

Follow Up

Average cached traded value over twenty sessions was INR 530,972,318. The trailing 5-session price return was 1.11%. The trailing 20-session price return was 4.90%. The trailing 60-session price return was 27.88%. The trailing 250-session price return was 39.99%.

Cached observations and evidence limits